There is a strong experimental rational for such strategies. From a mechanistic perspective, simvastatin increases nitric oxide (NO) availability in the cirrhotic liver circulation by enhancing the expression and activity of endothelial NOsynthase and therefore ameliorates portal hypertension, but also prevents endothelial dysfunction during endotoxaemia (2) . An anti-inflammatory effect is achieved through a decreased production of inflammatory cytokines and leukocyte migration to the sub-endothelial space. Importantly, mainly mediated by upregulation of the nuclear receptor KLF2, statins have anti-fibrotic effects due to inhibition of hepatic stellate cell activation by its paracrine interaction with endothelial sinusoidal cells (3).
In their article in Hepatology, Chang and co-authors used the Taiwan National Health Insurance database in a nested case-control study to estimate the effect of statins on the risk of decompensation, mortality and HCC in patients with cirrhosis. Index cases of cirrhosis were identified from a representative sample of 1,000,000 people who were followed from 2000 to 2013 (4). The authors used propensity score matching and finally selected 675 patients with cirrhosis in each of the statin-user and non-statin user group from a potential size of 1172 statin users. HCV, HBV and alcohol were the included aetiologies of cirrhosis.
Statin users were defined as cirrhotic patients with more than 28 cumulative (likely due to lower number of patients/events in this sub analysis).
An advantage of this study compared to other population studies is that it derives from a well-validated general population database, thus significantly reducing the risk of selection bias. There are inevitable weaknesses as with such retrospective analyses, which include the lack of patients with NASH cirrhosis, the absence of laboratory parameters (with ensuing inability to calculate and correct for the MELD and Child-Pugh score), a potential lead-time bias for the incident HCC cases and the low threshold (cDDD>28) to classify a patient as statin user. Nevertheless, the propensity score matching was robust and nonbleeding varices at baseline was added in the model to account for the presence of clinically significant portal hypertension. The dilution of the statin effect in individual aetiologies of cirrhosis is most likely due to type II error rather than selective effectiveness in viral hepatitis over alcohol-induced cirrhosis.
This study adds further observational evidence on the potential beneficial effects of statins in patients with cirrhosis. In large cohort studies, statin use was protective against significant fibrosis in patients with NAFLD (5) and was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 There have been two proof of concept prospective RCTs on the use of statins for cirrhosis so far. In a RCT of 59 patients, simvastatin given for one month significantly reduced portal pressure by an average of 8.3% and was associated with a marked improvement in liver indocyanine-green clearance, indicating a potential for improved liver function (9). Importantly, the effect on portal pressure was over and above that of non-selective beta-blockers. In a further RCT in 158 patients with decompensated cirrhosis due to previous variceal bleeding, addition of simvastatin to standard of care was independently associated with a survival benefit (HR=0.55) in those patients with Child Pugh A and B cirrhosis (10). The study is an important guidance to further study design; although the primary composite endpoint of reduction of rebleeding or death was not achieved, simvastatin had a significant effect in all cause mortality, mostly due to less bleeding or infection-related deaths, further reinforcing the pleiotropic statin effect (10). This is in keeping with data from pre-clinical cirrhotic models showing that statins protect from liver failure secondary to sepsis and hypovolemic shock (2) . In the BLEPS study, statins were no beneficial 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42 
